EXActDNA-003 Study (B-64/2023-05): Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
NSABP
This study is evaluating a new type of biomarker found in individuals who have cancer. A biomarker is found in blood, other body fluids, or tissues related to traces of cancer remaining after cancer treatments, or cancer that has returned (recurrent) after curative treatments were received. A biomarker may be used to see how completely a cancer responds to treatment.
Enrollment Form
This study is currently enrolling.